TY - JOUR
T1 - Timing of postoperative radiation therapy and survival in resected salivary gland cancers
T2 - Long-term results from a single institution
AU - Romine, Perrin E.
AU - Voutsinas, Jenna
AU - Wu, Vicky
AU - Tratt, Micah
AU - Liao, Jay
AU - Parvathaneni, Upendra
AU - Barber, Brittany
AU - Dillon, Jasjit
AU - Timoshchuk, Mari Alina
AU - Futran, Neal
AU - Houlton, Jeffrey
AU - Laramore, George
AU - Martins, Renato
AU - Eaton, Keith D.
AU - Rodriguez, Cristina
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/12
Y1 - 2021/12
N2 - Objectives: Timely administration of postoperative radiation therapy (PORT) impacts oncologic outcomes in resected squamous cell carcinomas of the head and neck. Salivary gland cancers (SGCs) are uncommon, and timing of PORT has not been extensively explored. We aimed to determine if the interval between surgery and PORT impacts outcomes in SGCs. Materials and Methods: This is a retrospective study of patients with SGCs who underwent curative intent surgical resection followed by adjuvant PORT. Locoregional recurrence free survival (LRFS), disease free survival (DFS), and overall survival (OS) were estimated using the Kaplan Meier method. A multivariate analysis explored the association between demographics, tumor characteristics, and PORT timing with oncologic outcomes using a stepwise Cox proportional hazards model. Results: 180 eligible patients were identified. The median time to PORT start was 61 (range 8–121) days. 169 (93.5%) of patients received neutron radiation. With a median follow up of 8.2 years in surviving patients, the 10-year OS and LRFS estimates were 61% and 53%. In a multivariate analysis, nodal involvement, histologic grade, and age at diagnosis were associated with OS, while nodal involvement, tumor size, and age at diagnosis were associated with LRFS and DFS. Time to PORT start or completion was not statistically associated with survival outcomes. Conclusion: SGC patients who underwent surgery in our tertiary institution received PORT within a median of 61 days after surgery. With long term follow up, PORT timing in this retrospective series was not associated with worse oncologic outcomes, and support timely administration of PORT.
AB - Objectives: Timely administration of postoperative radiation therapy (PORT) impacts oncologic outcomes in resected squamous cell carcinomas of the head and neck. Salivary gland cancers (SGCs) are uncommon, and timing of PORT has not been extensively explored. We aimed to determine if the interval between surgery and PORT impacts outcomes in SGCs. Materials and Methods: This is a retrospective study of patients with SGCs who underwent curative intent surgical resection followed by adjuvant PORT. Locoregional recurrence free survival (LRFS), disease free survival (DFS), and overall survival (OS) were estimated using the Kaplan Meier method. A multivariate analysis explored the association between demographics, tumor characteristics, and PORT timing with oncologic outcomes using a stepwise Cox proportional hazards model. Results: 180 eligible patients were identified. The median time to PORT start was 61 (range 8–121) days. 169 (93.5%) of patients received neutron radiation. With a median follow up of 8.2 years in surviving patients, the 10-year OS and LRFS estimates were 61% and 53%. In a multivariate analysis, nodal involvement, histologic grade, and age at diagnosis were associated with OS, while nodal involvement, tumor size, and age at diagnosis were associated with LRFS and DFS. Time to PORT start or completion was not statistically associated with survival outcomes. Conclusion: SGC patients who underwent surgery in our tertiary institution received PORT within a median of 61 days after surgery. With long term follow up, PORT timing in this retrospective series was not associated with worse oncologic outcomes, and support timely administration of PORT.
KW - Head and neck cancer
KW - Post-operative radiation therapy
KW - Quality of care
KW - Salivary gland cancer
UR - http://www.scopus.com/inward/record.url?scp=85119374608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119374608&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2021.105626
DO - 10.1016/j.oraloncology.2021.105626
M3 - Article
C2 - 34801976
AN - SCOPUS:85119374608
SN - 1368-8375
VL - 123
JO - Oral Oncology
JF - Oral Oncology
M1 - 105626
ER -